



From Nature for Life

Ad hoc NOTICE

Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)

CFO Martin Möller to leave Bioteest as planned at the end of his contract. Position of CFO to be filled in the near future

Dreieich, Germany, 6 March 2025. The Board of Management of Bioteest AG announces that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025.

The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future.

Martin Möller will continue to support Bioteest AG in an advisory capacity beyond the end of his contract.

Bioteest Aktiengesellschaft
The Board of Management

Bioteest AG
Landsteinerstr. 5
D-63303 Dreieich
www.bioteest.com

Disclaimer

This document contains forward-looking statements on the overall economic development and the business, earnings, financial and asset situation of Bioteest AG and its subsidiaries. These statements are based on the company's current plans, estimates, forecasts and expectations and are therefore subject to risks and uncertainties that could cause actual developments to differ materially from those anticipated. The forward-looking statements are only valid at the time of publication. Bioteest does not intend to update the forward-looking statements and does not assume any obligation to do so.

About Bioteest

Bioteest (www.bioteest.com) is a provider of biological therapeutics derived from human plasma. With a value-added chain that extends from preclinical and clinical development to worldwide sales, Bioteest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Bioteest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Bioteest has more than 2,500 employees worldwide. The ordinary and preference shares of Bioteest AG are listed in the Prime Standard on the German Stock Exchange. Since May 2022, Bioteest has been a part of the Grifols Group, headquartered in Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Baumann (Buttkereit)
Phone: +49-6103-801-4406
Mail: ir@bioteest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269

Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biostest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201

Preference shares: securities' ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate